GICS Sector : Healthcare
Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection.The company's pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23.The company was formerly known as Aeglea BioTherapeutics, Inc.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
Spyre Therapeutics Announces Grants of Inducement Awards
Dec -05
Spyre Therapeutics, Inc. $SYRE Shares Purchased by Intech Investment Management LLC
Dec -01
Spyre Therapeutics Announces Grants of Inducement Awards
Nov -07
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Nov -04
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody
Nov -04
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
Oct -24
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
Oct -15
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
Oct -14
Spyre Therapeutics' Human Enzyme Therapeutics growth is driven by increasing demand for rare genetic disorder treatments, advancements in gene editing technologies, and strategic partnerships. The 9.27% growth rate is also fueled by expanding research and development investments, growing awareness of lysosomal storage diseases, and a strong pipeline of novel enzyme replacement therapies.
ST-002 is a novel, orally bioavailable, small molecule inhibitor of the cGAS-STING pathway, which is a key regulator of the innate immune response.
ST-025 is a small molecule inhibitor of the NLRP3 inflammasome, a key regulator of the innate immune response.
ST-061 is a novel, orally bioavailable, small molecule inhibitor of the AIM2 inflammasome, which is a key regulator of the innate immune response.
Spyre Therapeutics, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing research and development in the biotechnology industry.
Spyre Therapeutics, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are specialized, making it difficult for customers to switch to alternative suppliers.
Spyre Therapeutics, Inc. relies on a few key suppliers for raw materials and equipment. While the company has some bargaining power due to its size, the suppliers also have some leverage due to the specialized nature of the products.
The biotechnology industry has high barriers to entry, including significant capital requirements, complex regulatory approvals, and specialized expertise. These barriers make it difficult for new entrants to compete with established companies like Spyre Therapeutics, Inc.
The biotechnology industry is highly competitive, with many established companies and new entrants vying for market share. Spyre Therapeutics, Inc. faces intense competition from companies with similar products and technologies.
| Value | |
|---|---|
| Debt Weight | 31.48% |
| Debt Cost | 3.95% |
| Equity Weight | 68.52% |
| Equity Cost | 18.52% |
| WACC | 13.93% |
| Leverage | 45.95% |
Value: 6.2
Growth: 7.6
Quality: 3.4
Yield: 0.0
Momentum: 10.0
Volatility: 4.7
1-Year Total Return ->
Value: 8.2
Growth: 8.0
Quality: 5.1
Yield: 0.0
Momentum: 5.0
Volatility: 2.0
1-Year Total Return ->
Value: 9.8
Growth: 5.8
Quality: 6.0
Yield: 0.0
Momentum: 0.0
Volatility: 1.0
1-Year Total Return ->
Value: 6.8
Growth: 6.8
Quality: 5.6
Yield: 0.0
Momentum: 1.0
Volatility: 1.3
1-Year Total Return ->
Value: 8.2
Growth: 4.3
Quality: 4.8
Yield: 0.0
Momentum: 0.5
Volatility: 1.0
1-Year Total Return ->
Value: 6.4
Growth: 0.3
Quality: 3.2
Yield: 0.0
Momentum: 0.5
Volatility: 1.0
1-Year Total Return ->